Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07728019) titled 'Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM' on July 22.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Condition:
CRC (Colorectal Cancer)
Intervention:
Radiation: SCRT
Drug: Retlirafusp alfa Injection
Drug: Bevacizumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: J...